BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 23137818)

  • 21. Phase I study of safety and immunogenicity of an Escherichia coli-derived recombinant protective antigen (rPA) vaccine to prevent anthrax in adults.
    Brown BK; Cox J; Gillis A; VanCott TC; Marovich M; Milazzo M; Antonille TS; Wieczorek L; McKee KT; Metcalfe K; Mallory RM; Birx D; Polonis VR; Robb ML
    PLoS One; 2010 Nov; 5(11):e13849. PubMed ID: 21079762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of delayed anthrax vaccine dose on Bacillus anthracis protective antigen IgG response and lethal toxin neutralization activity.
    Pittman PR; Fisher D; Quinn X; Schmader T; Barrera-Oro JG
    Vaccine; 2013 Oct; 31(44):5009-14. PubMed ID: 24026013
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative analysis of the immunologic response induced by the Sterne 34F2 live spore Bacillus anthracis vaccine in a ruminant model.
    Ndumnego OC; Köhler SM; Crafford J; van Heerden H; Beyer W
    Vet Immunol Immunopathol; 2016 Oct; 178():14-21. PubMed ID: 27496738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of mucoadhesive carrier adjuvant: toward an oral anthrax vaccine.
    Mangal S; Pawar D; Agrawal U; Jain AK; Vyas SP
    Artif Cells Nanomed Biotechnol; 2014 Feb; 42(1):47-57. PubMed ID: 23452384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A CpG-Ficoll Nanoparticle Adjuvant for Anthrax Protective Antigen Enhances Immunogenicity and Provides Single-Immunization Protection against Inhaled Anthrax in Monkeys.
    Kachura MA; Hickle C; Kell SA; Sathe A; Calacsan C; Kiwan R; Hall B; Milley R; Ott G; Coffman RL; Kanzler H; Campbell JD
    J Immunol; 2016 Jan; 196(1):284-97. PubMed ID: 26608924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine.
    Little SF; Ivins BE; Fellows PF; Pitt ML; Norris SL; Andrews GP
    Vaccine; 2004 Jan; 22(3-4):422-30. PubMed ID: 14670324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of non-toxic deletion mutants of protective antigen from Bacillus anthracis.
    Rhie GE; Park YM; Han JS; Yu JY; Seong WK; Oh HB
    FEMS Immunol Med Microbiol; 2005 Aug; 45(2):341-7. PubMed ID: 16019195
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A plant based protective antigen [PA(dIV)] vaccine expressed in chloroplasts demonstrates protective immunity in mice against anthrax.
    Gorantala J; Grover S; Goel D; Rahi A; Jayadev Magani SK; Chandra S; Bhatnagar R
    Vaccine; 2011 Jun; 29(27):4521-33. PubMed ID: 21504775
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanistic Analysis of the Effect of Deamidation on the Immunogenicity of Anthrax Protective Antigen.
    Verma A; Ngundi MM; Burns DL
    Clin Vaccine Immunol; 2016 May; 23(5):396-402. PubMed ID: 26912784
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of nasal immunization with protective antigen of Bacillus anthracis on protective immune response against anthrax toxin.
    Gaur R; Gupta PK; Banerjea AC; Singh Y
    Vaccine; 2002 Jun; 20(21-22):2836-9. PubMed ID: 12034111
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity of a subunit vaccine against Bacillus anthracis.
    Chichester JA; Musiychuk K; de la Rosa P; Horsey A; Stevenson N; Ugulava N; Rabindran S; Palmer GA; Mett V; Yusibov V
    Vaccine; 2007 Apr; 25(16):3111-4. PubMed ID: 17280756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacious, nontoxigenic Bacillus anthracis spore vaccines based on strains expressing mutant variants of lethal toxin components.
    Mendelson I; Gat O; Aloni-Grinstein R; Altboum Z; Inbar I; Kronman C; Bar-Haim E; Cohen S; Velan B; Shafferman A
    Vaccine; 2005 Dec; 23(48-49):5688-97. PubMed ID: 16039760
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bacillus anthracis Capsular Conjugates Elicit Chimpanzee Polyclonal Antibodies That Protect Mice from Pulmonary Anthrax.
    Chen Z; Schneerson R; Lovchik JA; Dai Z; Kubler-Kielb J; Agulto L; Leppla SH; Purcell RH
    Clin Vaccine Immunol; 2015 Aug; 22(8):902-8. PubMed ID: 26041039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A plant-produced protective antigen vaccine confers protection in rabbits against a lethal aerosolized challenge with Bacillus anthracis Ames spores.
    Chichester JA; Manceva SD; Rhee A; Coffin MV; Musiychuk K; Mett V; Shamloul M; Norikane J; Streatfield SJ; Yusibov V
    Hum Vaccin Immunother; 2013 Mar; 9(3):544-52. PubMed ID: 23324615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the compatibility of a second generation recombinant anthrax vaccine with aluminum-containing adjuvants.
    Jendrek S; Little SF; Hem S; Mitra G; Giardina S
    Vaccine; 2003 Jun; 21(21-22):3011-8. PubMed ID: 12798645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein.
    Price BM; Liner AL; Park S; Leppla SH; Mateczun A; Galloway DR
    Infect Immun; 2001 Jul; 69(7):4509-15. PubMed ID: 11401993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity and efficacy of an anthrax/plague DNA fusion vaccine in a mouse model.
    Albrecht MT; Eyles JE; Baillie LW; Keane-Myers AM
    FEMS Immunol Med Microbiol; 2012 Aug; 65(3):505-9. PubMed ID: 22515653
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nasal immunization with the mixture of PA63, LF, and a PGA conjugate induced strong antibody responses against all three antigens.
    Sloat BR; Shaker DS; Le UM; Cui Z
    FEMS Immunol Med Microbiol; 2008 Mar; 52(2):169-79. PubMed ID: 18194342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A combination of the TLR4 agonist CIA05 and alum promotes the immune responses to Bacillus anthracis protective antigen in mice.
    Wui SR; Kim HK; Han JE; Kim JM; Kim YH; Chun JH; Cho YJ; Lee NG
    Int Immunopharmacol; 2011 Sep; 11(9):1195-204. PubMed ID: 21492746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monitoring of ELISA-reactive antibodies against anthrax protective antigen (PA), lethal factor (LF), and toxin-neutralising antibodies in serum of individuals vaccinated against anthrax with the PA-based UK anthrax vaccine.
    Grunow R; Porsch-Ozcürümez M; Splettstoesser W; Buckendahl A; Hahn U; Beyer W; Böhm R; Huber M; vd Esche U; Bessler W; Frangoulidis D; Finke EJ
    Vaccine; 2007 May; 25(18):3679-83. PubMed ID: 17287051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.